关键数据
71.500今开
71.570最高
560.43K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
1.36%换手率
71.140昨收
67.160最低
27.13M成交额
亏损市盈率静
1.13市净率
0.00%股息率 TTM
-13.99%ROA
118.84052周最高
0.98量比
-2.03B净利润
41.13M总股本
-10.3076每股收益TTM
--Beta
-16.09%ROE
29.95052周最低
6.20%振幅
-35.08%毛利率
2.94B总市值
0.68回报/风险
4.69%风险率
操作建议
Grail Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名62/385位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价68.39。中期看,股价处于上升通道。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Grail Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Ionis Pharmaceuticals Inc
IONS
26
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Grail Inc简介
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代码GRAL
公司Grail Inc
CEORagusa (Robert)
网址https://grail.com/
公司股东
常见问题
Grail Inc(GRAL)的当前股价是多少?
Grail Inc(GRAL)的当前股价是 68.56。
Grail Inc股票的52周最高点是118.84。
Grail Inc股票的52周最低点是29.95。
现在Grail Inc(GRAL)的股票是买入、持有还是卖出?
根据分析师评级,Grail Inc(GRAL)的总体评级为买入,目标价格为68.39。
Grail Inc(GRAL)股票的每股收益(EPS TTM)是多少
Grail Inc(GRAL)股票的每股收益(EPS TTM)是-11.11。